Are prophylactic and therapeutic target concentrations different?: The case of lopinavir-ritonavir or lamivudine administered to infants for prevention of mother-to-child HIV-1 transmission during breastfeeding

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Foissac, Frantz ^a,b,c   Blume, Jörn ^d,e,f   Tréluyer, Jean Marc ^a,b,c,g   Tylleskär, Thorkild ^d   Kankasa, Chipepo ^h   Meda, Nicolas ⁱ   Tumwine, James K ^j   Singata Madliki, Mandisa ^e,f   Harper, Kim ^k   Illamola, Silvia M ^a,g   Bouazza, Naïm ^a,b,c   Nagot, Nicolas ^l,m   Van De Perre, Philippe ^l,m   Blanche, Stéphane ^a,n   Hirt, Déborah ^a,b,c,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Paris Descartes University   (France)

^c INSERM   (France)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF FORT HARE   (South Africa)

^f UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^g University Teaching Hospital ^*  (France)

^h UNIVERSITY OF ZAMBIA   (Zambia)

ⁱ UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^j MAKERERE UNIVERSITY   (Uganda)

^k WALTER SISULU UNIVERSITY   (South Africa)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m UNIV MONTPELLIER   (France)

ⁿ HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Breastfeeding; Pharmacokinetics; Preexposure prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR;

AREA UNDER THE CURVE; ARTICLE; BREAST FEEDING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; ELIMINATION RATE CONSTANT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; INFECTION PREVENTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ADVERSE EFFECTS; BAYES THEOREM; HIV INFECTIONS; MOTHER; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BAYES THEOREM; BREAST FEEDING; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; LOPINAVIR; MOTHERS; RITONAVIR;

EID: 85011003482     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01869-16     Document Type: Article

References (23)

1. Joint United Nations Programme on HIV/AIDS. 2013. UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
2. White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS. 2014. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst Rev 10:CD011323. https://doi.org/10.1002/14651858.CD011323.
3. WHO. 2016. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. WHO, Geneva, Switzerland.
4. Nagot N, Kankasa C, Meda N, Hofmeyr J, Nikodem C, Tumwine JK, Karamagi C, Sommerfelt H, Neveu D, Tylleskär T, Van de Perre P, PROMISE-PEP Group. 2012. Lopinavir/ritonavir versus lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial protocol ANRS 12174. BMC Infect Dis 12:246. https://doi.org/10.1186/1471-2334-12-246.
5. Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Maréchal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskär T, Van de Perre P, ANRS 12174 Trial Group. 2016. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 387:566-573. https://doi.org/10.1016/S0140-6736(15)00984-8.
6. Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE. 2012. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther 91:243-249. https://doi.org/10.1038/clpt.2011.218.
7. Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel J-R, Treluyer J-M, Capparelli EV, Lallemant M, Urien S. 2015. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Antivir Ther 20:225-223. https://doi.org/10.3851/IMP3016.
8. Bouazza N, Tréluyer J-M, Msellati P, Van de Perre P, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Hirt D, Urien S. 2013. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients. AIDS 27:761-768. https://doi.org/10.1097/QAD.0b013e32835caad1.
9. Bouazza N, Urien S, Blanche S, Hirt D, Foissac F, Benaboud S, Tréluyer J-M, Frange P. 2014. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Pediatr Infect Dis J 33:e213-e218. https://doi.org/10.1097/INF.0000000000000298.
10. Porte CJ, Back D, Blaschke T, Boucher CAB, Fletcher CV, Flexner C, Gerber J, Kashuba ADM, Schapiro JM, Burger DM. 2006. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 3:4-12.
11. Gengiah TN, Moosa A, Naidoo A, Mansoor LE. 2014. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm 36:70-85. https://doi.org/10.1007/s11096-013-9861-1.
12. Blumenthal J, Haubrich R. 2013. Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. Expert Opin Pharmacother 14:1777-1785. https://doi.org/10.1517/14656566.2013.812072.
13. Krakower DS, Mayer KH. 2015. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs 75:243-251. https://doi.org/10.1007/s40265-015-0355-4.
14. Desmond AC, Moodley D, Conolly CA, Castel SA, Coovadia HM. 2015. Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life. BMC Pediatr 15:23. https://doi.org/10.1186/s12887-015-0340-9.
15. Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT. 2003. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 34:482-490. https://doi.org/10.1097/00126334-200312150-00006.
16. Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, Young N, Opilo W, Lallemant M, Walker AS, Burger D, Gibb DM. 2014. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in African HIV-infected children. J Acquir Immune Defic Syndr 66:148-154. https://doi.org/10.1097/QAI.0000000000000135.
17. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. 1998. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 178:368-374. https://doi.org/10.1086/515641.
18. de Vries-Sluijs TEMS, Dieleman JP, Arts D, Huitema ADR, Beijnen JH, Schutten M, van der Ende ME. 2003. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 42:599-605. https://doi.org/10.2165/00003088-200342060-00009.
19. Hirt D, Warszawski J, Firtion G, Giraud C, Chappuy H, Lechenadec J, Benaboud S, Urien S, Blanche S, Tréluyer J-M. 2013. High exposure to zidovudine during the first 2 weeks of life and concentration-toxicity relationships. J Acquir Immune Defic Syndr 63:555-562. https://doi.org/10.1097/QAI.0b013e3182908c00.
20. Hines RN. 2008. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267. https://doi.org/10.1016/j.pharmthera.2008.02.005.
21. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer J-M, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S, ANRS French Perinatal Cohort Study Group. 2011. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 306:70-78. https://doi.org/10.1001/jama.2011.915.
22. Food and Drug Administration. 2011. FDA drug safety communication: serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. Food and Drug Administration, Rockville, MD. http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm#data-summary.
23. Illamola SM, Labat L, Benaboud S, Tubiana R, Warszawski J, Tréluyer JM, Hirt D. 2014. Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods. J Chromatogr B Analyt Technol Biomed Life Sci 965:216-223. https://doi.org/10.1016/j.jchromb.2014.06.034.